Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T cells in R/R B-ALL
NCT04653493Phase 1Unknown
- Sponsor
- Sabz Biomedicals
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Sabz Biomedicals. Primary endpoint: Maximum Tolerated Dose and Dose-limiting Toxicities at 30 days. Status: unknown.
02
Drugs
CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04653493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653493.